Lunai Bioworks Faces Nasdaq Delisting Due to Bid Price Non-Compliance; Files Appeal
Summary
Lunai Bioworks Inc. received a notice from Nasdaq regarding the delisting of its securities due to non-compliance with the minimum bid price rule, exacerbated by a recent reverse stock split, though the company has filed an appeal.
Key Events
-
Nasdaq Delisting Notice Received
On February 6, 2026, Lunai Bioworks Inc. received a written notice from Nasdaq's Listing Qualifications Department, informing the company of Nasdaq staff's determination to delist its securities.
-
Non-Compliance with Minimum Bid Price
The delisting is due to non-compliance with Nasdaq Listing Rule 5550(a)(2), as the company's bid price closed below $1.00 per share for 30 consecutive business days from December 23, 2025, through February 5, 2026.
-
Ineligible for Compliance Period
The company is not eligible for the standard 180-calendar-day compliance period because it effected a 1-for-10 reverse stock split on September 30, 2025, within the prior one-year period, as per Nasdaq Listing Rule 5810(c)(3)(A)(iv).
-
Company Files Appeal
Lunai Bioworks Inc. has filed a request for a hearing before the Nasdaq Hearings Panel to appeal the delisting determination. This action will stay the suspension of securities and the filing of Form 25 pending the hearing outcome, though success is not assured.
Analysis
Lunai Bioworks Inc. has received a delisting notice from Nasdaq due to its failure to maintain the minimum $1.00 bid price requirement. This is a critical event as the company is not eligible for a compliance period, having executed a 1-for-10 reverse stock split within the last year. While the company has filed an appeal, there is no guarantee of success. Delisting from Nasdaq would severely impact the company's liquidity, investor confidence, and ability to raise capital, potentially forcing it to trade on over-the-counter markets, which are less regulated and have lower trading volumes. This situation highlights significant operational and financial challenges.
At the time of this filing, LNAI was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.2M. The 52-week trading range was $0.63 to $14.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.